PercAssist's PSCA System - Intrapericardial Mechanical Circulatory Support (MCS) System for Cardiogenic Shock Presented at the TCT24

PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced that new data was presented at two sessions at the Transcatheter Cardiovascular Therapeutics (TCT24) Conference in Washington, DC, Oct. 27-30, 2024.

PercAssist Announces Multiple Patients Treated In the EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

PercAssist, Inc. announces additional successful in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.

PercAssist Announces First Patient Treated in EUREKA Study of PSCA System for Hemodynamic Support in Chronic Heart Failure

PercAssist, Inc. announces the successful first in human use of its percutaneous subxiphoid cardiac assist (PSCA) device to support an acute myocardial infarction patient with decompensated heart failure at NA Homolce Hospital in Prague with hemodynamic stabilization of the patient for a five day period.

Innovative Heart Failure Treatment to be Highlighted at the American College of Cardiology

PercAssist to present cutting-edge heart failure technology at major cardiology annual meeting.

PercAssist one of ten finalists at the ADA 2022 Silicon Valley Leaders Forum HealthTech Showcase

Company's technology showcased at prestigious competition.